

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

JeKo-1

RRID:CVCL_1865

Type: Cell Line

Proper Citation

RRID:CVCL_1865

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1865

Proper Citation: RRID:CVCL_1865

Description: Cell line JeKo-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Mantle cell lymphoma

Defining Citation: [PMID:9753063](#), [PMID:12683869](#), [PMID:16448697](#), [PMID:16960149](#), [PMID:17332242](#), [PMID:21746927](#), [PMID:22460905](#), [PMID:25315077](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26194763](#), [PMID:26439697](#), [PMID:27397505](#), [PMID:27697772](#), [PMID:28196595](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Korean., Part of: MD Anderson Cell Lines Project., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JeKo-1

Synonyms: Jeko-1, JEKO-1, JeKo 1, Jeko1, JEKO1, JEKO

Cross References: BTO:BTO_0006444, EFO:EFO_0005387, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-

7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-3006, BioGRID_ORCS_Cell_line:1542, BioSample:SAMN01821569, BioSample:SAMN01821639, BioSample:SAMN03473289, BioSample:SAMN10988454, cancercellines:CVCL_1865, CCRID:3101HUMTCHu194, Cell_Model_Passport:SIDM01038, ChEMBL-Cells:ChEMBL4295383, ChEMBL-Targets:ChEMBL4296445, CLS:305078, Cosmic:1047110, Cosmic:1881781, Cosmic:2088016, Cosmic:2296999, Cosmic:2756237, Cosmic-CLP:1327765, DepMap:ACH-000357, DSMZ:ACC-553, DSMZCellDive:ACC-553, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1327765, GEO:GSM95563, GEO:GSM104460, GEO:GSM119537, GEO:GSM155081, GEO:GSM155082, GEO:GSM155083, GEO:GSM629490, GEO:GSM629491, GEO:GSM887168, GEO:GSM888240, GEO:GSM907519, GEO:GSM1044966, GEO:GSM1044967, GEO:GSM1044968, GEO:GSM1044969, GEO:GSM1374577, GEO:GSM1669949, GEO:GSM2322619, GEO:GSM3150246, IARC_TP53:25017, LiGeA:CCL_844, Lonza:1060, PharmacDB:JeKo1_678_2019, PRIDE:PXD004746, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1865, PubChem_Cell_line:CVCL_1865, Wikidata:Q54898569

ID: CVCL_1865

Record Creation Time: 20220427T220645+0000

Record Last Update: 20260920T004225+0000

Ratings and Alerts

No rating or validation information has been found for JeKo-1.

No alerts have been found for JeKo-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 198 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Roleder C, et al. (2026) Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Cancer research communications, 6(5), 1192.

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine, 7(7), 102885.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Shukla D, et al. (2025) CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target. *Cancer immunology research*, 13(6), 867.

Lei W, et al. (2024) Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. *Cell discovery*, 10(1), 5.

Liu P, et al. (2024) Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma. *American journal of cancer research*, 14(6), 2921.

Guo S, et al. (2024) CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. *Blood advances*, 8(11), 2635.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Li Q, et al. (2024) TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma. *PloS one*, 19(9), e0310889.

Zhang Y, et al. (2023) USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1. *International journal of medical sciences*, 20(5), 616.

Li L, et al. (2023) Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. *Haematologica*, 108(6), 1616.

Osorio-Rodríguez DA, et al. (2023) Anti-ROR1 CAR-T cells: Architecture and performance. *Frontiers in medicine*, 10, 1121020.

Merrien M, et al. (2023) 2-Arachidonoylglycerol Modulates CXCL12-Mediated Chemotaxis in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. *Cancers*, 15(5).

Granau AM, et al. (2023) Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma. *Cancers*, 15(2).

Jiang VC, et al. (2023) Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. *The Journal of clinical investigation*, 133(3).

Jiang Z, et al. (2023) Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1. *Scientific reports*, 13(1), 8389.

Pourzia AL, et al. (2023) Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. *Cell death & disease*, 14(4), 267.

Lv Y, et al. (2023) The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy. Cell communication and signaling : CCS, 21(1), 16.